Dr. Bridgette Peake earned her B.S. in human biology from Michigan State University, and completed her M.S in molecular biology at Western Illinois University in 2010. She earned her doctorate in Molecular Pharmacology from Emory University in 2017. Her studies focused on overcoming mechanisms of chemoresistance in breast cancer. Her dissertation work investigating HER2-positive breast cancer led to the identification of GDF15 as a driving cytokine of cellular invasion and metastasis. Dr. Peake played an active role on the executive member of Emory’s Black Graduate Student Organization for most of her graduate career. She then interned at the Emory Office of Technology Transfer, where she evaluated academic intellectual property for commercialization and advancement.
In 2018, she received an offer for a competitive postdoctoral position. The Coulter Foundation funded her work and she received dual mentorship from collaboration between biomedical engineers at Emory University and clinicians at the VA Hospital of Atlanta. Her postdoctoral studies investigated the preclinical role of antisense technology consisting of gold nanoparticles conjugated with deoxyribozymes (DNAzymes) for the regulation of pro-inflammatory cytokines commonly upregulated in COPD and lung cancer. She is passionate about biomedical innovation, clinical discovery and identifying opportunities for the advancement of patient care. Dr. Peake is currently a Medical Science Liaison, specializing in cultivating relationships with physicians, field education and utilizing her molecular oncology background to provide clinical insight and drive innovative technology implementation.